Apimeds Pharmaceuticals US, Inc.(APUS)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Apimeds Pharmaceuticals US, Inc. (APUS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. APUS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Apimeds Pharmaceuticals US, Inc. reports net income of $-20.2M, free cash flow of $-5.7M. Top institutional holders of APUS by reported 13-F value include Hemenway, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. APUS trades on the NYSE exchange and files with the SEC under CIK 1894525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apimeds Pharmaceuticals US, Inc. directly from SEC EDGAR.